Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruoxetine sustained-release vs fluoxetine in adolescents with major depressive disorder
ChiCTR2500108779Phase 4Recruiting
- Sponsor
- Beijing Anding Hospital
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of fluoxetine in major depressive disorder (MDD) (4 arms), sponsored by Beijing Anding Hospital. Primary endpoint: Change in MADRS total score from baseline to week 8. Started Sep 2025; status: recruiting.
02
Drugs
fluoxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2500108779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108779.